Short Bowel Syndrome Market Growing at a CAGR of 25.53% During 2017 to 2021 Says a New Report at ReportsnReports.com
PUNE, India, June 9, 2017 /PRNewswire/ --
Short Bowel Syndrome Market report has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global short bowel syndrome (SBS) market for 2017-2021. To calculate the market size, the report considers the sales of the drugs and related nutraceutical products.
Browse 42 Exhibits, 3 Major Company Profiles, spread across 70 pages available at http://www.reportsnreports.com/reports/1022383-global-short-bowel-syndrome-sbs-market-2017-2021.html.
The latest trend gaining momentum in the short bowel syndrome market is increased awareness of GI disorders. Pharmaceutical companies and national and local government bodies such as the health ministry and municipalities are conducting programs to spread awareness of GI disorders. Many NGOs also conduct camps to educate people and raise the awareness level. Drug manufacturers supply visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This is done to increase the knowledge of the individuals about a particular GI disorder.
The following companies as the key players in the global short bowel syndrome (SBS) market: Emmaus Medical, Merck, and Shire. Other Prominent Vendors in the market are: Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma. Order a copy of Global Short Bowel Syndrome Market 2017-2021 research report at http://www.reportsnreports.com/purchase.aspx?name=1022383.
According to the report, one of the major drivers for this short bowel syndrome market is special drug designations. As the market is dominated by a few drugs and the pipeline also demonstrates the same, the special designation will provide more opportunity for revenue generation and to expand geographically. These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug's sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors to develop a product for a rare disease.
Related Reports:
Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021 - This market research study identifies AstraZeneca, Merck, Pfizer, and Sanofi as the leading players in the global hypertrophic cardiomyopathy therapeutics market.
Global Dyslipidemia Drugs Market 2017-2021 - With the presence of numerous small and larger vendors, the global dyslipidemia drugs market is largely competitive. Competition is observed from the regional players globally, and there are numerous new manufacturers entering the market.
Global Erythropoietin Drugs Market 2017-2021- The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact:
Ritesh Tiwari
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune - 411013.
Maharashtra, India.
+ 1-888-391-5441
[email protected]
Connect with Us:
LinkedIn: http://www.linkedin.com/company/reportsnreports
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Share this article